Citius Pharmaceuticals Accounts Receivables 2011-2026 | CTXR

Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.

Examples of accounts receivable

Customers have not paid invoices for delivered products
An advance has been paid to a supplier, but goods have not yet been received
Employees have not reported on accountable amounts
The government must refund tax overpayments
Outstanding loans issued

Importance of accounts receivable in company analysis

Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment.
Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages.
Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)

Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)

If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.

Quarterly Accounts Receivables Citius Pharmaceuticals

2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
4.05 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
4.05 M	4.05 M	4.05 M

Accounts Receivables of other stocks in the Biotechnology industry

Issuer	Accounts Receivables	Price	% 24h	Market Cap	Country
AgeX Therapeutics AGE	57 K	-	-10.17 %	$ 12.2 K	USA
AIkido Pharma AIKI	200 K	-	1.93 %	$ 17.4 M	USA
I-Mab IMAB	130 M	-	-	$ 866 M	China
Amarin Corporation plc AMRN	127 M	$ 14.67	-0.07 %	$ 6.09 B	Irlanda
Albireo Pharma ALBO	3.27 M	-	-0.23 %	$ 916 M	USA
Aptinyx APTX	257 K	-	-39.0 %	$ 4.57 M	USA
Arena Pharmaceuticals ARNA	1.65 M	-	-6.81 %	$ 3.04 B	USA
Ayala Pharmaceuticals AYLA	234 K	-	-	$ 7.46 M	Israel
Acorda Therapeutics ACOR	17.3 M	-	-24.86 %	$ 820 K	USA
bluebird bio BLUE	300 K	-	-	$ 546 M	USA
Acasti Pharma ACST	802 K	-	4.01 %	$ 150 M	Canada
Avid Bioservices CDMO	16.6 M	-	-	$ 789 M	USA
Adverum Biotechnologies ADVM	886 K	-	-	$ 86.2 M	USA
Advaxis ADXS	234 K	-	-9.65 %	$ 45.9 M	USA
Autolus Therapeutics plc AUTL	109 K	$ 1.29	-3.01 %	$ 329 M	Britain
CEL-SCI Corporation CVM	54.9 K	$ 3.47	-1.7 %	$ 221 M	USA
BeiGene, Ltd. BGNE	865 M	-	0.49 %	$ 251 B	Cayman-islands
Denali Therapeutics DNLI	2.17 M	$ 19.74	-12.17 %	$ 3.25 B	USA
BioDelivery Sciences International BDSI	56.9 M	-	-4.8 %	$ 255 M	USA
Cara Therapeutics CARA	2.76 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	411 K	-	-	$ 3.74 B	USA
Enlivex Therapeutics Ltd. ENLV	28 K	$ 1.09	-9.17 %	$ 22.4 M	Israel
Enochian Biosciences ENOB	432 K	-	-	$ 40.5 M	USA
Equillium EQ	3.74 M	$ 2.06	-	$ 118 M	USA
Esperion Therapeutics ESPR	140 M	$ 2.85	3.26 %	$ 592 M	USA
Eton Pharmaceuticals ETON	11.8 M	$ 23.45	-1.64 %	$ 631 M	USA
China SXT Pharmaceuticals SXTC	1.3 M	$ 1.32	-5.2 %	$ 1.88 M	China
CRISPR Therapeutics AG CRSP	25 M	$ 47.55	0.98 %	$ 4.28 B	Schweiz
Arbutus Biopharma Corporation ABUS	1.45 M	$ 4.45	-1.77 %	$ 853 M	Canada